Fig. 3: Antibodies against S14P5 and S21P2 linear B-cell epitopes neutralise SARS-CoV-2. | Nature Communications

Fig. 3: Antibodies against S14P5 and S21P2 linear B-cell epitopes neutralise SARS-CoV-2.

From: Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Fig. 3

a–b Localisation and sequences of a SARS-CoV-2 specific S14P5 and b pan-CoV S21P2 epitopes on spike (S) protein (PDB: 6VSB) are shown. Each S monomer is denoted as either pink, blue or orange. c–e Pooled sera of COVID-19 patients (n = 6) were added to plates coated with the corresponding peptides to deplete specific antibodies. c–d Validation of depletion by peptide-based ELISA against c depleted or d non-depleted peptides. Data of depleted sera (white bar) were normalised to percentages of the non-depleted sera (grey bar). Data are from one experiment in duplicate. Dotted line represents healthy sera mean value. e Non-depleted and peptide-specific antibody-depleted pooled sera were mixed with SARS-CoV-2 pseudovirus for 1 hour before infection of CHO-ACE2 cells for 48 hours. Percentage of pseudovirus neutralisation relative to the non-depleted sera, are shown. Data are presented as mean ± SD in triplicates. Statistical analysis was carried out with one-sample t test for each experiment (*p < 0.05, **p < 0.01). Figure is representative of two independent experiments. Source data are provided as a Source Data File.

Back to article page